This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related letters  • Similar articles in JAMA  Topic Collections  • Venous Thromboembolism  • Oncology  • Brain Cancer  • Oncology, Other  • Cardiovascular System  • Statistics and Research Methods  • Drug Therapy  • Drug Therapy, Other  • Gastroenterology  • Liver/ Biliary Tract/ Pancreatic Diseases  • Hematology/ Hematologic Malignancies  • Anemias  • Alert me on articles by topic  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In Reply: The original intent of our analysis was to evaluate risks for VTE when cancer patients received ESAs vs placebo/control.¹ At the time we initiated our study, the most recent data had been reported by the Cochrane Collaboration in 2006.² In response to a 2007 report of the FDA ODAC that ESA administration to cancer patients was associated with increased mortality risks,³ we evaluated mortality outcomes. As indicated in our JAMA article, the 2006 Cochrane review was used as the primary data source and was supplemented by trials reported more recently (ie, from the end of the review period for the Cochrane review [April 2005] to January 17, 2008), as well as by trials presented at the 2007 ODAC meeting. However, we erroneously interpreted the Cochrane review as including trials administering iron to the ESA group but not to the control group and therefore included these trials in our . . . [Full Text of this Article]

Charles L. Bennett, MD, PhD, MPP
cbenne@northwestern.edu
VA Chicago Healthcare System
Chicago, Illinois

Michael Henke, MD
University Hospital of Freiberg
Freiburg, Germany

Stephen Y. Lai, MD, PhD
University of Texas M. D. Anderson Cancer Center
Department of Head and Neck Surgery
Houston

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED LETTERS

Erythropoiesis-Stimulating Agents in the Treatment of Cancer-Associated Anemia
Julia Bohlius, Andreas Engert, and Guido Schwarzer
JAMA. 2008;300(24):2854-2855.
EXTRACT | FULL TEXT  

Erythropoiesis-Stimulating Agents in the Treatment of Cancer-Associated Anemia
Ozgur Kara, Omer Dizdar, and Kadri Altundag
JAMA. 2008;300(24):2855.
EXTRACT | FULL TEXT